Filing Flows › Pulmonx (LUNG) › Q2 2026 › vs Q2 2025
Pulmonx (LUNG) Q2 2026 vs Q2 2025 (year over year)
Pulmonx's revenue fell $1.1M (-5%) from $23.9M in Q2 2025 to $22.8M in Q2 2026.
Pulmonx, Q2 2026: revenue $22.8M (-5% year over year), operating margin -39.8%, net loss $10.1M, operating cash flow −$5.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $22.8M | $23.9M | −$1.1M | -5% |
| Net loss | $10.1M | $15.2M | −$5.1M | -34% |
| Costs & expenses | $32.8M | $39.0M | −$6.2M | -16% |
| Operating costs | $31.8M | $38.7M | −$6.8M | -18% |
| Interest & other, net | $890K | $192K | $698K | +364% |
| Income tax | $133K | $177K | −$44K | -25% |
| Cost of revenue | $5.0M | $6.7M | −$1.6M | -25% |
| Research & development | $5.0M | $5.3M | −$272K | -5% |
| SG&A | $21.8M | $26.7M | −$4.9M | -18% |
| Operating cash sources | $10.1M | $15.2M | −$5.1M | -34% |
| Depreciation | $200K | $300K | −$100K | -33% |
| Share-based compensation | $3.7M | $6.2M | −$2.5M | -40% |
| Working capital & other | $968K | $4.8M | −$3.8M | -80% |
| Cash used in operations | $5.2M | $3.9M | $1.3M | +33% |
| Net loss absorbed | $10.1M | $15.2M | −$5.1M | -34% |
Questions
How much did Pulmonx's revenue grow year over year in Q2 2026?
Pulmonx's revenue fell $1.1M (-5%) from $23.9M in Q2 2025 to $22.8M in Q2 2026.